Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts. Show more
Location: 1210-1220 Washington St., Newton, MA, 02465, United States | Website: https://acumenpharm.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
84.2M
52 Wk Range
$0.85 - $3.36
Previous Close
$1.39
Open
$1.40
Volume
52,695
Day Range
$1.34 - $1.40
Enterprise Value
-30.28M
Cash
143.4M
Avg Qtr Burn
-29.44M
Insider Ownership
11.46%
Institutional Own.
67.89%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sabirnetug (ACU193) Details Alzheimer's disease | Phase 2 Data readout | |
Sabirnetug (ACU193) w/ ENHANZE® Details Alzheimer's disease | Phase 1 Update |